The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to ...

Exxel Pharma is eyeing a listing on the NYSE American to fund human trials for a drug class that has previously struggled to ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

However, there are certain things AI can't do -- and may never be able to do. One of them is to cure diseases. Biotech companies that develop and market breakthrough therapies for, thus far, ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst ...

UK biotech showed resilience in a tough 2025 for healthcare funding, suggesting investor interest could grow in 2026.

Biotech stock Anaptysbio cleared a trendline entry near 50 on Monday. Shares are also in a base with a buy point of 52.47.